思路迪医药股份宣布,其核心产品恩沃利单抗(Envafolimab)的补充申请已获得国家药品监督管理局(NMPA)正式受理。此次申请旨在推动该药物从有条件批准向常规批准过渡,标志着公司在新药审批进程中迈出关键一步。
思路迪医药股份宣布,其核心产品恩沃利单抗(Envafolimab)的补充申请已获得国家药品监督管理局(NMPA)正式受理。此次申请旨在推动该药物从有条件批准向常规批准过渡,标志着公司在新药审批进程中迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.